Epitan raises $8 million in private placement

By Renate Krelle
Wednesday, 11 August, 2004

EpiTan (ASX: EPT) has raised AUD$7.98 million via a private placement of 10.5 million fully paid ordinary with two European investors.

The shares were issued at AUD$0.76, a 6.4 per cent discount to the three-month volume weighted average price of AUD$0.91.

8.5 million shares were placed with FM Fund Management, run out of Zurich by hedge fund manager Florian Homm. Its Absolute Return Europe Fund is now a substantial shareholder in EpiTan, holding 6.8 per cent of the company’s shares.

A further 2 million shares were placed with UK biotech investment fund Mercury Investments.

Epitan also issued 6.6 million unlisted options exercisable over three years at AUD$1.03, which would provide it with a further AUD$6.87 in cash. EpiTan’s executive chairman and CEO, Dr Wayne Millen said the placement bought Epitan’s cash reserves to approximately AUD$13 million.

At time of writing shares in Epitan were trading at $0.87.

Related News

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd